Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
No change in Timelines. Getting to capacity and commissioning was and remains Q4, with steady state Q1. This is also backed up by no change in production guidance of 15,196oz from Jul22-Jun23.
MRE included Batch 3
https://caracalgold.com/wp-content/uploads/2022/09/Caracal-Gold-PLC_Corporate-Presentation_SEPT-2022-WEBSITE.pdf
a few updates :
- Construction underway for a full scale heap leaching plant
- Projected AISC of $1000-1,100/oz once construction & ramp up is completed.
- Finalising acquisition of Nyakafuru Gold Project in Tanzania that has the potential to produce
50,000oz per annum.
MRE confirmed as JORC compliant
Oncimmune
@OncimmuneECDT
·
1h
We’re excited to share the launch of our new website! Home to our biomarker discovery, targeted panels, bioinformatics & data science services. Rediscover http://oncimmune.com and our #ImmunoINSIGHTS platform today! #WebLaunch #TeamOncimmune #ImmuneBiomarkers #Biomarkers
POG is only down is US$, It's up today in all other currencies.
It's £1480 in GBP currently +0.5%, £83 off all time high close. Although that day was the spike on 8th March, so if you forget a couple of days around then, it's only £40-50 off an all time high.
GCAT future profits and valuation is in GBP, so GBP POG is the only price I look at.
Medicare price for EarlyCDT(aka Nodify CDT) is $649 per test, as mentioned in recent Biodesix conference call
https://edge.media-server.com/mmc/p/rf64jw58
A bit of news here
CCL now offers EarlyCDT Lung test - identifying lung cancer risk earlier
Company news, Oncology
4 August 2022
Cambridge Clinical Laboratories is now running the Oncimmune EarlyCDT Lung test in its Cambridge laboratory. The EarlyCDT Lung test is a simple finger prick blood test which results can indicate whether an individual has an increased risk of lung cancer.
A useful test for those worried about lung cancer, those whose family members have had it and those who have been exposed to environmental factors that may increase risk, such as smoking. EarlyCDT Lung can detect lung cancer on average four years before standard care and has shown, in a large NHS trial, that it can reduce late stage lung cancer presentation by 36%.*
The impact of Covid-19 isn’t isolated to just those getting the virus. The NHS is struggling, with waiting times for cancer referral and treatment at record high. With 80% of lung cancer cases diagnosed in the later stages of the disease this new availability of the EarlyCDT Lung test could make a huge difference.
CCL, based in Milton Cambridge, is a leading lab with an objective to bring new technologies for diagnostics to the UK.
CCL CEO Dr Anthony Cooke says: “2020 threw a huge curveball for the world in the form of the Covid-19 pandemic, as a result Cancer healthcare has been hugely impacted. The new tests we are launching will help to ease the pressure of the NHS and support patients to take more of a lead with their healthcare. CCL wants to help; we know our tests will improve the lives of many.”
https://www.camclinlabs.co.uk/news/earlycdt
APR,
We have to remember that both plant 1 and 2 will be out for a couple several week each.
The plan was to first decouple plant 2 and then upgrade before doing plant 1. The 532 oz avg per month will take into account the main plant 1 being out completely, but as plant 2 is decoupled at that stage, gold can be produced as we as at plant 3.
I'm also surprised that they needed to correct, although happy with the "on track" comment.
It's plain to see by the foot note that it's for the financial year ending, not calendar year. This is standard for other companies.
But it was a pointless original tweet, before Robbies good one, from a historic presentation. Like the other tweets recently from the same presentation, including the one with the old resource and planned end Q2 update. Why bother for a forward looking company.
Not sure if st brides do it now, but bring back JB!
APR,
"GCAT have already stated that Plant 1 & 2 upgrades have now been delayed until Q1/2 2023 "
Plant 2 has been out(decoupling was previously mentioned) and Plant 1 will be upgraded soon for commissioning late 2022. Whether the de-coupling affects Plant 1 production...maybe?
But I'm expecting similar production, if not down on Q1. I also like to be conservative :-)
The Elution plant still needs to be upgraded and until then gold dore produced is going to be constrained IMO.
As JC said, it's not about current production this year, it's about reconfiguring and upgrading everything for 2k p/m steady state in early 2023.
The plan is coming together...exciting times ahead on many fronts!
It will be later in the year for the next MRE, with a better grade. They've got the tonnes and grade for their 24k oz/pa plan, so no point spending the money on consultants for JORC compliance on a regular basis.
Not expecting anything from the Nairobi listing, as Kenyan investors are still able to "buy the dream" on the LSE, if they have a good broker. Similar to the German investors, who solely use LSE(Robbie mentioned this in one Interview as well), not the Frankfurt exchange. Last trade on Frankfurt was months ago, so might be worth ditching it?
Nice to see a bit of blue, but still well below Robbie's 4M purchases at avg 1.04p a couple of months back. Took a few this am, but there wasn't much stock around.